Sanofi Stock Up 2.8% in September: What Lies Ahead?

On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion. The stock rose 1.2% that day from its previous day’s closing price. It traded at its 52-week high of $50.64 on October 6, 2017. It registered its 52-week low of $37.43 on May 9, 2018. Currently, SNY stock is trading above its 50-day moving average of $42.89 as well as its 200-day moving average of $40.89.

On September 13, Sanofi announced that it will refocus its two global business units and make certain organizational changes. That day, SNY stock rose 2.4%. On September 12, Sanofi and its partner Regeneron Pharmaceuticals announced that the FDA accepted its supplemental BLA (biologics license application) for Praluent injection. That day, Sanofi stock rose 2%.

On September 3, Sanofi announced the approval of its aTTP (acquired thrombotic thrombocytopenic purpura) drug Cablivi for adults in Europe. However, on September 4, Sanofi was charged with corruption by the U.S. Securities and Exchange Commission, for which Sanofi agreed to pay resolution settlement charges of $25 million. However, it neither admitted nor denied the corruption charges. On September 4, Sanofi stock fell 1%.

Year-to-date, Sanofi stock has risen 4.3%. However, it has fallen 9.9% over the last 12 months. By comparison, GlaxoSmithKline (GSK), Novo Nordisk (NVO), and Eli Lilly (LLY) have returned 0.30%, -1.4%, and 26%, respectively, over the last year.

Over the last 12 months, the Health Care Select Sector SPDR ETF (XLV) and the S&P 500 Index have risen 16.9% and 16.2%, respectively.